BR100 Decreased By (-1.2%)
BR30 Decreased By (-1.31%)
KSE100 Decreased By (-0.95%)
KSE30 Decreased By (-0.95%)
AGHA 6.32 Decreased By ▼ -0.05 (-0.78%)
BECO 4.27 Decreased By ▼ -0.10 (-2.29%)
BML 62.45 Decreased By ▼ -0.19 (-0.3%)
BOP 31.23 Decreased By ▼ -0.39 (-1.23%)
CNERGY 11.59 Decreased By ▼ -0.18 (-1.53%)
CSIL 5.72 Decreased By ▼ -0.37 (-6.08%)
FCCL 61.54 Decreased By ▼ -0.55 (-0.89%)
FFL 15.02 Increased By ▲ 0.29 (1.97%)
FNEL 1.23 Increased By ▲ 0.03 (2.5%)
KEL 6.26 Increased By ▲ 0.10 (1.62%)
KOSM 5.56 Decreased By ▼ -0.12 (-2.11%)
LOTCHEM 24.68 Decreased By ▼ -0.37 (-1.48%)
MLCF 104.08 Decreased By ▼ -1.19 (-1.13%)
NBP 175.28 Decreased By ▼ -5.29 (-2.93%)
NCPL 52.77 Decreased By ▼ -0.56 (-1.05%)
NPL 54.12 Decreased By ▼ -0.67 (-1.22%)
OGDC 313.39 Decreased By ▼ -2.70 (-0.85%)
PACE 9.20 Decreased By ▼ -0.19 (-2.02%)
PAEL 35.80 Increased By ▲ 0.36 (1.02%)
PIBTL 13.47 Decreased By ▼ -0.32 (-2.32%)
PPL 221.81 Decreased By ▼ -3.54 (-1.57%)
PRL 79.08 Decreased By ▼ -1.31 (-1.63%)
PTC 46.85 Decreased By ▼ -1.17 (-2.44%)
SSGC 23.87 Decreased By ▼ -0.54 (-2.21%)
TBL 9.31 Decreased By ▼ -0.07 (-0.75%)
TELE 7.39 Decreased By ▼ -0.20 (-2.64%)
TPL 25.11 Decreased By ▼ -0.23 (-0.91%)
TPLP 12.51 Decreased By ▼ -0.59 (-4.5%)
TREET 26.25 Increased By ▲ 1.21 (4.83%)
TRG 53.44 Decreased By ▼ -1.39 (-2.54%)
By

LONDON: The Bill & Melinda Gates Foundation has given $23.6 million to US-based life science company Micron Biomedical to fund the first ever mass production of needle-free vaccine technology.

The technology works by delivering the vaccine via dissolvable microneedles attached to the skin on a patch-like device.

Global health experts have long argued for the potential of similar technology to boost the uptake of life-saving shots.

It is simpler to transport and administer than traditional injections, particularly in low-income countries where reaching all of the children who need vaccines remains challenging. But scaling up production has been a hurdle.

A trial in Gambia earlier this year showed that Micron’s device delivered the measles-rubella vaccine, produced by the Serum Institute of India, to adults, babies and toddlers as safely and effectively as syringes, and produced a similar immune response.

The technology “could help overcome some of the most substantial barriers to eradicating measles and rubella globally”, said James Goodson, senior scientist in the immunization division at the US Centers for Disease Control and Prevention (CDC), which has also partnered with Micron.

It reduces the need for a cold chain for distribution, and does not require a trained professional to give the vaccine. It could also help those with a fear of injections, the company said in a statement on Thursday.

The funding will support the development of a manufacturing facility to help make around 10 million devices annually, for larger clinical trials and then wider use, subject to approvals from regulatory authorities.

The company has had several other grants from Gates, to help deliver the technology to “underserved populations around the world”, Micron’s CEO Steven Damon said.

Comments

Comments are closed for this article.